Patients get extreme to obtain hepatitis drug that's 1 percent the cost outside US
Having trouble reading this email? View online.

Archive Volume 16, Issue 6 November/December 2015
Published by the Hemophilia Association of the Capital Area |

Important message from HACA

This is the last issue of the HCV/HIV Newsletter, also known as HACA Today. With the advent of the web and social media, important research and other articles of interest can be found more quickly online than through the printed page. HACA extend a heart-felt thanks to John Dring and Mark Antell for serving as editors of the HCV/HIV Newsletter for the past several years. The newsletter was started in in the year 2000.

With liver disease progression in HIV/HCV, statins offer benefit

Statins are associated with decreased progression of liver disease among patients who are coinfected with HIV and hepatitis C virus, according findings from a single-institution cohort study reported at IDWeek 2015.

Pioneer in AIDS research set to begin trial for new vaccine

A trial for a new AIDS vaccine is set to begin soon. While there have been over 100 AIDS vaccines developed over the years, Dr. Robert Gallo, who in 1984 co-discovered that HIV triggered AIDS, has worked on this one for the last 15.

Hepatitis C-related mortality continues to increase in the US
NAM aidsmap

Deaths related to hepatitis C virus infection continue to rise in the US despite the advent of highly effective interferon-free therapy, according to a CDC study presented at IDWeek 2015 in San Diego, California.

FDA warns of liver damage from AbbVie's hepatitis C treatments
The Wall Street Journal (registration)

The U.S. Food and Drug Administration warned that AbbVie Inc.'s new hepatitis C treatments may cause serious liver harm among patients with underlying liver disease — a blow to some of a new generation of drugs seen as a big advance for hepatitis patients.

Fat-coated drugs keep immune cells free of HIV

Protease inhibitors are a class of antiviral drugs that are commonly used to treat HIV, the virus that causes AIDS. Now, scientists have designed a new delivery system for these drugs that, when coupled with another drug, rid immune cells of HIV and kept the virus in check for long periods.

2 studies identify promising new anti-retroviral strategy to combat HIV-1
News Medical

A pair of studies by researchers at the University of Massachusetts Medical School, the University of Trento in Italy, and the University of Geneva in Switzerland, point to a promising new anti-retroviral strategy for combating HIV-1.

Hemophilia Association of the Capital Area

Mailing Address
10560 Main Street, Suite 309
Fairfax, VA 22030
Office Phone

This email was sent by the Hemophilia Association of the Capital Area, powered by Powered by Corporate Briefs
Engage your customer base. Launch your Corporate Brief today.

Archive | View Online